CRISPR Therapeutics (NASDAQ:CRSP) vs. Mindset Pharma (OTCMKTS:MSSTF) Critical Analysis

Mindset Pharma (OTCMKTS:MSSTF) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current ratings for Mindset Pharma and CRISPR Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mindset Pharma	0	0	0	0	0.00
CRISPR Therapeutics	1	7	10	1	2.58

CRISPR Therapeutics has a consensus target price of $67.78, indicating a potential upside of 41.23%. Given CRISPR Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Mindset Pharma.

Profitability

This table compares Mindset Pharma and CRISPR Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mindset Pharma	N/A	N/A	N/A
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Institutional and Insider Ownership

69.2% of CRISPR Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Mindset Pharma and CRISPR Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mindset Pharma	N/A	N/A	N/A	N/A	N/A
CRISPR Therapeutics	$3.51 million	1,318.70	-$581.60 million	($6.22)	-7.72

Mindset Pharma has higher earnings, but lower revenue than CRISPR Therapeutics.

Summary

CRISPR Therapeutics beats Mindset Pharma on 7 of the 10 factors compared between the two stocks.

About Mindset Pharma

Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.